Reports
Non-Invasive Prenatal Testing (NIPT) Market Trends Report, 2026-2034
REPORT DETAILS
Report Code:
PM1836
No. of Pages:
129
Format:
PDF
Published Date:
Base Year:
2025
Author:
Shreyas Shirsat
Historical Data:
2021-2024
REPORT DETAILS
Report Code:
PM1836
Published Date:
No. of Pages:
129
Historical Data:
2021-2024
Format:
PDF
Author:
Shreyas Shirsat
Base Year:
2025
ABOUT THIS REPORT
Non-Invasive Prenatal Testing (NIPT) Market Size, Share, Trends, Industry Analysis Report: By Gestation Period (0-12 Weeks, 13-24 Weeks, 25-36 Weeks), By Component, By Method, By Application, By End Use, By Region – Market Forecast, 2026–2034
Non-Invasive Prenatal Testing (Nipt) Market Overview
The non-invasive prenatal testing (NIPT) market size was valued at USD 4.86 billion in 2025. It is expected to register a CAGR of 11.0% from 2026 to 2034. The growing need for early fetal risk assessment propels the market growth. Increasing awareness of chromosomal abnormalities drives NIPT demand. The broader adoption of advanced sequencing technologies in prenatal care fuels the market expansion.
Key Takeaways
- In 2025, North America dominated the global market with 44.92%. The leading position is attributed to the presence of advanced healthcare infrastructure and robust adoption of advanced technologies.
- The Asia Pacific NIPT market is expected to register the highest CAGR of 12.6% from 2026 to 2034. Increasing disposable incomes and enhanced healthcare spending are contributing to market growth.
- In 2025, the cell-free DNA in maternal plasma tests segment held the largest revenue share of 45.15%. This is due to its superior accuracy and minimal risk compared to traditional invasive methods.
- The trisomy segment dominated the market with 55.10% revenue share in 2025. NIPT is important for detecting common chromosomal abnormalities like Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome). These conditions are common and have serious effects on prenatal care. Early and accurate detection is vital for expectant parents.
- The consumables segment accounted for a 44.24% revenue share in 2025. This is owing to the high volume of recurring testing and reagents required in clinical settings.
Note: Figures and projections outlined in this report are the result of Polaris Market Research’s proprietary analytical processes, grounded in the latest available datasets and market observations
Market Statistics
- 2025 Market Size: USD 4.86 billion
- 2034 Projected Market Size: USD 12.47 billion
- CAGR (2026–2034): 11.0%
- North America: Largest market in 2025
Industry Dynamics
- Rising adoption of technological advancements in sequencing technologies and bioinformatics services drives the NIPT market expansion.
- The rise in maternal age is a significant driver for the NIPT industry growth.
- The growing focus on patient security and comfort fuels the requirement for non-invasive prenatal testing.
- Various countries have prohibited the application of NIPT for sex selection on non-medical backgrounds. This factor hinders the growth of the market.
AI Impact on Non-Invasive Prenatal Testing Market
- AI technology is used to enhance genetic data analysis. It improves accuracy in detecting chromosomal abnormalities, such as trisomy conditions.
- Machine learning (ML) algorithms reduce false positives and negatives, which increases test reliability.
- AI-based bioinformatics platforms accelerate sequencing data interpretation, reducing turnaround time.
- Predictive analytics enables early risk assessment and personalized prenatal insights.
- AI supports integration of large genomic datasets. It enables better clinical decision-making.
- Continuous learning models refine test performance over time.
 Market.png)
To Understand More About this Research: Download Sample Report
What is Non-Invasive Prenatal Testing?
Non-invasive prenatal testing (NIPT) refers to prenatal screening tests. The tests are designed to assess the risk of fetal chromosomal abnormalities. They use cell-free DNA from a maternal blood sample. This approach avoids invasive procedures like amniocentesis or chorionic villus sampling.. NIPT has become an important component of modern prenatal screening. It offers early risk assessment with a less invasive patient experience. Industry and clinical sources consistently position NIPT as a screening method rather than a standalone diagnostic tool. create a need for reliable and less invasive prenatal screening options. NIPT decreases the burden associated with invasive procedures.. It is increasingly favored in routine prenatal care discussions.
Why the NIPT Market is Growing?
The NIPT market is growing substantially, mainly due to the increasing prevalence of prenatal genetic disorders and rising consumer demand for early, accurate assessments of fetal health. The growing incidence of Edward's syndrome, Down syndrome, and other chromosomal abnormalities has intensified the need for effective non-invasive testing. NIPT is a safer option than traditional methods, such as amniocentesis. It delivers accurate results with a reduced risk of miscarriage.
According to the World Health Organization (WHO), an estimated 6% of babies across the world are born with a congenital disorder. This results in hundreds of thousands of associated deaths. Rising prevalence of this disorder propels the need for stronger prenatal screening pathways, improved maternal-fetal risk stratification, and better access to early screening technologies. It supports timely counseling and care planning. This highlights the need for better prenatal screening methods, including NIPT. The testing detects these disorders early. It also improves outcomes for newborns and their families.
NIPT provides a safer profile and lower discomfort than traditional invasive methods. Additionally, NIPT offers high accuracy in detecting chromosomal abnormalities. It offers a very low rate of false positives and negatives. This high level of accuracy, integrated with its non-invasive nature, instills confidence in its reliability, making it the best choice among pregnant mothers seeking dependable prenatal screening. As a result, rising patient preference for NIPT is driving substantial growth in the market.
The increasing focus on patient security and comfort continues to drive the demand for NIPT screening. The fact that over 95% of patients reported high levels of satisfaction with NIPT, according to a study in Prenatal Diagnosis, is a clear testament to its appeal and effectiveness. This reflects a broader trend towards more patient-friendly and adequate prenatal care solutions.
Market Dynamics
Rising Technological Advancements in Sequencing Technologies and Bioinformatics
The market is developing rapidly due to continuous technological advancements in sequencing technologies and bioinformatics. Innovations in next-generation sequencing (NGS) have improved the ability to analyze fetal DNA fragments present in maternal plasma. It is supporting greater precision, broader screening menus, and higher operational efficiency within laboratory settings. These improvements are strengthening the commercial appeal of NIPT across mature and developing healthcare markets.
Advancements in bioinformatics are improving the interpretation of complex genomic data. It enables more reliable risk classification. The innovations help laboratories scale testing volumes without compromising analytical quality. In practical terms, this means providers can improve throughput and reduce turnaround variability. It also offers more comprehensive screening panels, including expanded chromosome-level insights in some markets. As a result, sequencing and analytics capabilities are becoming major differentiators in the competitive landscape.
Automation is becoming equally important as assay sensitivity. Laboratories increasingly evaluate NIPT platforms on detection capability and workflow simplicity. They are also used for sample throughput, quality control performance, and compatibility with existing sequencing infrastructure. This is particularly important for regional laboratory networks and private diagnostic chains seeking to expand prenatal screening capacity without proportionately increasing labor intensity. Therefore, rising technological advancements in sequencing technologies and bioinformatics boost the market growth.
Rise in Maternal Age
The rise in maternal age is a significant driver for the market. Women are increasingly choosing to have children later in life. Maternal age, particularly pregnancies in women aged 35 and above, is a well-established risk factor for chromosomal abnormalities. According to CDC data, women aged 30–34 had 211,989 more births in 2023 than in 1990 (i.e., 24% increase). Women aged between 35 and 39 had 287,048 more births in 2023 than in 1990 (i.e., a 90% increase). Those aged 40 and above had 96,809 more births in 2023 than in 1990 (i.e., a 193% increase). NIPT provides a safe, reliable, and early way to detect genetic disorders. Additionally, NIPT meets the need for effective prenatal diagnostic solutions. NIPT helps manage the associated risks and improve pregnancy outcomes. Thus, the growing number of older expectant mothers fuels the testing demand.
Market Restraints and Challenges
High cost of NIPT remains a barrier in lower-income and underinsured populations. Further, reimbursement inconsistency across public and private payer systems limits widespread access in some countries. Some healthcare settings have limited access to genetic counseling before and after testing. This adversely impacts patient understanding and appropriate use.
Another challenge is the need for clear communication about the tests scope and interpretation. NIPT is very effective for common trisomies. However, broader panels for microdeletions, sex chromosome aneuploidy screening, and rare chromosomal abnormalities may require more careful clinical interpretation. Also, they may vary by market practice. Panel menus are expanding. Thus, providers and laboratories must balance innovation with evidence-based use. They must emphasize patient counseling quality and local regulatory requirements.
NGS vs PCR vs Microarray in NIPT: Comparative Matrix
NGS provides high sensitivity, multiplexing ability, and scalability. These advantages make it perfect for large commercial labs and broader screening panels. PCR-based methods are popular for low-cost, quick, and targeted applications. They are especially in demand in emerging markets or for confirmatory testing. Microarray technologies fall in between. They enable economical detection of chromosomal abnormalities, but they do not offer the flexibility and depth of NGS.
|
Parameter |
Next-Generation Sequencing (NGS) |
PCR (qPCR / dPCR) |
Microarray (CMA) |
|
Sensitivity |
Very high. i.e., >99% for common aneuploidies. Strong SNV detection |
High for targeted, known variants. Limited for rare/unknown variants |
Moderate to high for copy number variations. Weaker for SNVs |
|
Throughput |
Very high (massively parallel; thousands of targets/sample) |
Low–moderate (limited targets per run) |
Moderate (many probes but less scalable than NGS) |
|
Cost |
High upfront and operational cost |
Low cost per test; cost-effective for small panels |
Moderate; generally cheaper than NGS but higher than PCR |
|
Panel Expansion |
Highly flexible. Supports genome-wide, exome, and expanded panels |
Limited. Requires redesign for each new target |
Fixed probe design. Limited flexibility once array is set |
|
Lab Scalability |
Excellent. Scalable for high-volume centralized labs |
Limited scalability. Best for low-volume or targeted testing |
Moderate; scalable but less efficient than NGS for large volumes |
|
Turnaround Time |
Longer. Complex workflow. Bioinformatics required |
Fast. Rapid amplification and detection |
Moderate. Hybridization and analysis steps required |
|
Variant Detection Scope |
Broad (aneuploidy, CNVs, SNVs, indels) |
Narrow (specific known mutations) |
Focused on CNVs and chromosomal imbalances |
|
Operational Complexity |
High (requires advanced infrastructure & bioinformatics) |
Low (widely available, simple workflow) |
Moderate (specialized equipment, less complex than NGS) |
Guidelines, Reimbursement, and Clinical Adoption Trends
There is an increasing shift in professional guidance toward broader prenatal screening access. ACOG NIPT guidance states that prenatal genetic screening and diagnostic testing options should be discussed. It also mentions that the testing must be offered to all pregnant patients. ACMG has strongly recommended noninvasive prenatal screening over traditional screening methods. It is recommended for common fetal trisomies in singleton and twin gestations. Clinical acceptance supports broader physician adoption and earlier test utilization. It also leads to stronger reimbursement discussions across key markets.
Reimbursement remains a powerful but uneven growth factor. Many regions are improving private insurance coverage, public payer support, or institutional reimbursement pathways. In such regions, NIPT adoption tends to accelerate due to lower out-of-pocket barriers and broader physician confidence in recommending the test. By contrast, in markets with fragmented reimbursement and limited access to genetic counseling, uptake can remain concentrated in urban private-care settings. This makes NIPT reimbursement strategy one of the most important NIPT market growth drivers.
 Market info.png)
Segment Analysis
By Method
The NIPT market segmentation includes cell-free DNA in maternal plasma tests, biochemical screening tests, ultrasound detection, and others. In 2025, the cell-free DNA in maternal plasma tests segment dominated the market with 45.15%. CfDNA has superior accuracy profile and minimal procedural burden than invasive prenatal testing methods. These features propel demand for cell-free DNA screening. CfDNA analysis is the foundational technology behind modern non-invasive prenatal screening methods. Technological advancements in sequencing, assay design, and data analysis are increasing. It enhances the sensitivity, specificity, and scalability of cfDNA testing. Innovations make it the most commercially significant modality in the market.
In May 2024, Natera launched a cfDNA-based fetal RhD test. It will expand the practical applications of blood-based prenatal screening. It is expected to demonstrate continued product innovation within the women’s health diagnostics. The launch also highlights how platform innovation can extend beyond traditional trisomy screening and create new differentiation within the NIPT ecosystem.
Biochemical screening tests and ultrasound remain important components market. They are positioned as complementary or comparative methods rather than the core technology of NIPT itself.
|
Method |
Description |
Suitable for |
Advantages |
|
Maternal plasma cell-free DNA testing |
Analyzes small amounts of DNA fragments from the fetus that can be found in the mother’s bloodstream. |
Early diagnosis of chromosomal abnormalities such as Down’s syndrome. |
High sensitivity and non-invasive |
|
Biochemical testing |
Calculates the levels of certain hormones or proteins present in the maternal blood. |
Evaluation of potential risks of genetic diseases. |
Cost-efficient and widely available |
|
Ultrasound detection |
Imaging technique aimed at observing the fetus’ development and any abnormal physical features. |
Monitoring the progress of the fetus’ growth and possible defects. |
Conventional and safe procedure |
|
Others |
Combination or enhanced versions of the above techniques. |
Prenatal genetic disease risk assessment. |
Increased accuracy rate |
By Application
The segmentation includes monosomy, trisomy, microdeletion syndrome, and others. The trisomy segment dominated the market with 55.10% revenue share in 2025. NIPT is required in screening for common chromosomal abnormalities. It is used for Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome). These are the most established and commercially relevant NIPT use cases. This supports high test demand across clinical settings. The trisomy market growth is fueled by strong awareness and clinical familiarity. Also, NIPT can provide high-performing risk screening through a simple blood draw, propelling the segment growth. Providers and patients prioritize early, low-risk prenatal screening. Thus, trisomy screening remains the most mature and scalable application area for NIPT vendors and diagnostic laboratories.
Interest in microdeletion screening, sex chromosome aneuploidy reporting, and expanded panel offerings is rising. Their demand is particularly increasing among laboratories seeking product differentiation and among patients seeking more comprehensive prenatal insights. However, these applications require careful positioning. Evidence thresholds, reimbursement support, and physician comfort levels may differ from those associated with common trisomy screening.
 Market seg.png)
Regional Overview
By region, the study provides market insights into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2025, North America led the global market with 44.92% revenue share. The North America non-invasive prenatal testing market growth is attributed to the presence of advanced healthcare infrastructure and high awareness levels. Also, robust adoption of advanced technologies propels the growth. The U.S. and Canada have well-established healthcare systems. They are equipped with the latest diagnostic tools and technologies. This facilitates the widespread availability and use of NIPT. Furthermore, strong regulatory frameworks and healthcare policies support the use of NIPT. It is fostering an environment conducive to market growth.
The North America NIPT market expansion is driven by comparatively favorable commercialization conditions, including stronger payer engagement. Broader access to genetic testing laboratories and a mature women’s health diagnostics landscape propel the expansion. This allows vendors to compete on analytical performance and on panel breadth, turnaround time, automation capability, and physician support services.
The Asia Pacific non-invasive prenatal testing market is expected to have the highest CAGR of 12.6% from 2026 to 2034. Rising disposable incomes and increasing healthcare spending lead to higher adoption rates. In China and India, economic growth and a growing middle class drive the demand for modern medical technologies, including NIPT. Intense competition comes from strategies like price competitiveness, technological innovation, geographic expansion, and partnerships. These factors promote innovation and better access for expectant parents. Supportive regulations in China and India help simplify the adoption of NIPT technologies. These factors make Asia Pacific the fastest-growing region in the global market.
The Asia Pacific market is also being shaped by laboratory localization, strategic partnerships, and region-specific product deployment models. Vendors work to expand access while maintaining affordability. Thus, the region is expected to remain a major growth engine for the global NIPT market. Healthcare modernization trends in several Asian countries are helping accelerate this shift.
 Market reg.png)
Key Players and Competitive Analysis Report
Competitive landscape of the market is intense. Major NIPT companies continuously invest in assay development, workflow optimization, laboratory partnerships, and geographic expansion. It will help them improve their market positions. Testing breadth, sequencing infrastructure, automation compatibility, turnaround time, evidence generation, and reimbursement support influence the competition.
Manufacturers are improving analytical performance and reducing operational complexity. They aim to expand the range of detectable abnormalities through improved sequencing and bioinformatics. Their strategies include partnerships with regional labs, assays localization, and clinical validation. The companies invest in developing unique offerings like fetal RhD screening and wider genome-wide screening. These competitive dynamics are reshaping the value proposition across established and emerging markets
Major market players include Agilent Technologies, Eurofins LifeCodexx GmbH, F. Hoffmann-La Roche Ltd., Illumina, Inc., Laboratory Corporation of America Holdings, MedGenome Labs Ltd., Myriad Women’s Health, Natera, Inc., QIAGEN, Quest Diagnostics, and Thermo Fisher Scientific, Inc.
List of Key Companies
- Agilent Technologies, Inc.
- Centogene N.V.
- Eurofins LifeCodexx GmbH
- F. Hoffmann-La Roche Ltd.
- Illumina, Inc.
- Laboratory Corp. of America Holdings
- MedGenome Labs Ltd.
- Myriad Women’s Health, Inc.
- Natera, Inc.
- Progenity, Inc.
- Qiagen
- Quest Diagnostics, Inc.
- Thermo Fisher Scientific, Inc.
Future of NIPT Market
The market for NIPT is projected to expand steadily owing to growing utilization of prenatal screening tests and greater awareness about genetic diseases. Increased utilization of the tests in low-risk pregnancies will drive market growth. Technological developments in genomics and sequencing will improve test efficiency and accuracy. Rising use of precision medicine is expected to further drive market development in the coming years.
Non-Invasive Prenatal Testing Industry Developments
- April 2026: Gene Solutions launched triSure at the Taiwan Association of Obstetrics and Gynecology (TAOG) 2026 Annual Meeting. triSure is a new non-invasive prenatal screening technology designed to expand testing beyond common aneuploidies. (Source: genesolutions.com)
- January 2026: Natera, Inc. launched its expanded 21-gene Fetal Focus single gene non-invasive prenatal test (sgNIPT). It is supported by new findings from the blinded prospective EXPAND clinical trial. (Source: natera.com)
- February 2025: Yourgene Health (part of the Novacyt group of companies) announced the launch of IONA Care+ in the UK. It is a fully comprehensive non-invasive prenatal screening service for genetic conditions. The service will utilize Yourgene’s IONA® Nx NIPT Workflow to deliver safe, fast, and accurate NIPT results. (Source: novacyt.com)
Non-Invasive Prenatal Testing Market Segmentation
By Gestation Period Outlook (Revenue – USD Billion, 2021–2034)
- 0–12 Weeks
- 13–24 Weeks
- 25–36 Weeks
By Component Outlook (Revenue – USD Billion, 2021–2034)
- Consumables
- Instruments
- Software
- Services
By Method Outlook (Revenue – USD Billion, 2021–2034)
- Cell-Free DNA in Maternal Plasma Tests
- Ultrasound Detection
- Biochemical Screening Tests
- Others
By Application Outlook (Revenue – USD Billion, 2021–2034)
- Monosomy
- Trisomy
- Microdeletion Syndrome
- Others
By End Use Outlook (Revenue – USD Billion, 2021–2034)
- Diagnostic Centers
- Hospitals and Clinics
- Others
By Regional Outlook (Revenue – USD Billion, 2021–2034)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
What Our Analysts Predict?
The market is evolving from a high-growth prenatal screening niche into a more sophisticated global diagnostics category. The market development will be shaped by sequencing innovation and reimbursement expansion. Further, broader clinical adoption and increasing patient demand for early non-invasive risk assessment would propel the NIPT demand in the coming years. While the market outlook remains strong, competitive advantage will increasingly depend on platform reliability, workflow scalability, and evidence-based application expansion.
Non-Invasive Prenatal Testing (NIPT) Market Report Scope
|
Report Attributes |
Details |
|
Market Size in 2025 |
USD 4.86 billion |
|
Market Size in 2026 |
USD 5.39 billion |
|
Revenue Forecast in 2034 |
USD 12.47 billion |
|
CAGR |
11.0% from 2026 to 2034 |
|
Base Year |
2025 |
|
Historical Data |
2021–2024 |
|
Forecast Period |
2026–2034 |
|
Quantitative Units |
Revenue in USD billion, 2021–2034 and CAGR from 2026 to 2034 |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Regional Scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, regions, and segmentation. |
FAQ's
The global NIPT market was valued at USD 4.86 billion in 2025. It is projected to reach USD 12.47 billion by 2034, growing at a CAGR of 11.0% during 2026–2034.
NIPT screens for chromosomal conditions, including trisomies 21, 18, and 13. It is also used for sex chromosome abnormalities and certain microdeletions.
Cell-free DNA in maternal plasma tests led the market with 45.15% in 2025. They represent the core technology of modern NIPT. The method offers strong clinical utility with a non-invasive blood draw.
The consumables segment accounted for a 44.24% revenue share in 2025.
North America led the global market with a revenue share of 44.92% in 2025. It is driven by advanced healthcare infrastructure and strong reimbursement policies.
Rising preference for non-invasive testing drives market growth. However, high procedure costs is one of the major restraints limiting global adoption.
Reimbursement reduces out-of-pocket cost barriers. It can accelerate physician adoption and patient access. Favorable reimbursement policies can boost routine prenatal screening uptake
Page last updated on: Apr-2026
Download Sample Report of Non-Invasive Prenatal Testing (NIPT) Market
Please fill out the form to request a customized copy of the research report.
